Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Daiichi Sankyo
Merck
Medtronic
Boehringer Ingelheim
McKinsey

Generated: July 15, 2019

DrugPatentWatch Database Preview

Patent: 9,662,322

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,662,322
Title:Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
Abstract: This invention provides a method for treating or for reducing ambulatory deterioration in a human patient diagnosed to be afflicted with relapsing-remitting multiple sclerosis (RRMS) and having a high baseline disability score according to the Kurtzke Expanded Disability Status Scale (EDSS), comprising periodically administering to only the patient diagnosed with RRMS and having a high baseline disability score an amount of laquinimod effective to treat the patient or to reduce ambulatory deterioration. This invention further provides pharmaceutical compositions and packages comprising an effective amount of laquinimod for treating a human patient diagnosed to be afflicted with RRMS and having a high baseline disability score according to the EDSS.
Inventor(s): Knappertz; Volker (Potomac, MD)
Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva, IL)
Application Number:14/946,586
Patent Claims:see list of patent claims

Details for Patent 9,662,322

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva, IL) ➤ Sign Up RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Citi
Baxter
Cantor Fitzgerald
Daiichi Sankyo
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.